Drug class in one race
AKT (inhibitor) drugs for HR+/HER2- Metastatic Breast Cancer
3 tracked AKT (inhibitor) drugs in the HR+/HER2- Metastatic Breast Cancer race. The class explanation lives on the AKT (inhibitor) page; the full indication pipeline across every mechanism is on the HR+/HER2- Metastatic Breast Cancer page.
1 approved / phase 42 Phase 3
Head-to-head evidence: Afuresertib vs Capivasertib · Capivasertib vs NTQ1062